TRML - NASDAQ
Tourmaline Bio, Inc.
$47.98
+0.0000%Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
At a Glance
Live SnapshotTourmaline Bio, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Tourmaline Bio, Inc. Balance Sheet
TRML • NASDAQ
| Tourmaline Bio, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
ASSETS | ||||||
CURRENT ASSETS | ||||||
30.5M | 140.7M | 8.3M | 18.6M | 17.6M | 39M | |
227.8M | 62.2M | 0.0 | 225.4M | 131.9M | 0.0 | |
258.3M | 203M | 8.3M | 244M | 149.5M | 39M | |
0.0 | 0.0 | 54K | 1.9M | 804K | 1.8M | |
10.5M | 5.9M | 0.0 | 640K | 459K | 39K | |
268.8M | 208.9M | 8.3M | 246.5M | 150.8M | 40.8M | |
NON-CURRENT ASSETS | ||||||
267K | 447K | 570K | 4.8M | 2M | 1.1M | |
36.6M | 0.0 | 216K | 0.0 | 0.0 | 0.0 | |
3.3M | 974K | 0.0 | 104K | 14K | 21K | |
40.2M | 1.4M | 786K | 4.9M | 2M | 1.1M | |
309M | 210.3M | 9.1M | 251.4M | 152.8M | 41.9M | |
LIABILITIES | ||||||
CURRENT LIABILITIES | ||||||
3.6M | 1.1M | 401K | 2.6M | 767K | 0.0 | |
3.6M | 1.1M | 401K | 2.6M | 767K | 0.0 | |
1.3M | 1.7M | 800K | 3.3M | 1.4M | 0.0 | |
0.0 | 221K | 162K | 0.0 | 0.0 | 0.0 | |
227K | 221K | 162K | 0.0 | 0.0 | 0.0 | |
3.8M | 1.8M | -162K | 2.1M | 1.2M | 2.3M | |
8.9M | 5M | 1.4M | 8M | 3.4M | 2.3M | |
NON-CURRENT LIABILITIES | ||||||
23K | 57K | 27.1M | 626K | 1.4M | 63K | |
40K | 251K | 27.5M | 626K | 1.4M | 63K | |
244K | 415K | 504K | 0.0 | 0.0 | 0.0 | |
8.9M | 5.3M | 28.8M | 8.6M | 4.8M | 2.4M | |
SHAREHOLDERS' EQUITY | ||||||
0.0 | 0.0 | 27.1K | 0.0 | 186.2M | 56.7M | |
3K | 2K | 4K | 4K | 1K | 3K | |
435M | 267M | 195K | 333.7M | 4.9M | 0.0 | |
-135.3M | -62.1M | -19.9M | -90.8M | -43M | -20.3M | |
296K | 67K | -721K | -78K | -13K | -3K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.2M | |
300.1M | 205M | -19.7M | 242.8M | 148M | 39.6M | |
300.1M | 205M | -19.7M | 242.8M | 148M | 39.6M | |
SUMMARY | ||||||
309M | 210.3M | 9.1M | 251.4M | 152.8M | 41.9M | |
264.4M | 62.2M | 216K | 225.4M | 131.9M | 0.0 | |
244K | 415K | 504K | 0.0 | 0.0 | 0.0 | |
-30.3M | -140.3M | -7.8M | -18.6M | -17.6M | -39M | |
25,690,936 | 25,690,936 | 25,690,936 | 25,690,936 | 25,690,936 | 25,690,936 |
SEC Filings
TRML - Filing history and reports
No SEC filings available for TRML
Related Guides
Continue your TRML research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.